Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Biocon Biologics Confirms Viatris North American Transition Will Complete By End Q3 2023

Aug 12, 2023

According to the Business Standard Biocon Biologics’ CEO has confirmed the transition of the North American part of Viatris’ global biosimilars business to Biocon Biologics will complete by the end of this quarter, less than a year after the companies signed a $3.34B acquisition of Viatris’ biosimilars business on 29 November 2022.  Biocon Biologics and Viatris have had a two-year transition services agreement in place following finalisation of the acquisition in November last year.  Biocon Biologics will also consider an IPO once Viatris is integrated.

On 5 July 2023, Biocon Biologics announced it had completed a third of the integration of Viatris’ biosimilars business in over 70 countries in ‘emerging markets’.